SPRO

NASDAQ 已收盘

Spero Therapeutics

0.74 USD
▼-0.08-10.20%
盘后 0.79 +6.36%
2026-11-20
市值
$43.23M
市盈率
7.83
EPS
-0.51
股息率
—
52 周区间
0.73 – 3.08
成交量
425.33K
Beta
1.56
目标价
5.33
52W 低 0.7352W 高 3.08
价格走势

公司简介

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, man...

关联新闻